Immunotherapy in advanced anal cancer: Is the beginning of a new era?
暂无分享,去创建一个
F. Ciardiello | E. Maiello | T. Troiani | D. Ciardiello | E. Martinelli | M. Di Maio | P. Parente | Tiziana Pia Latiano | Luigi Pio Guerrera | Brigida Anna Maiorano
[1] C. Borg,et al. Second-line treatment after docetaxel, cisplatin and 5-fluorouracil in metastatic squamous cell carcinomas of the anus. Pooled analysis of prospective Epitopes-HPV01 and Epitopes-HPV02 studies , 2022, European Journal of Cancer.
[2] P. Ascierto,et al. Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study. , 2022, The lancet. Gastroenterology & hepatology.
[3] F. Ciardiello,et al. Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival. , 2022, Clinical colorectal cancer.
[4] F. Tong,et al. The Research Progress of PD-1/PD-L1 Inhibitors Enhancing Radiotherapy Efficacy , 2021, Frontiers in Oncology.
[5] M. Fassan,et al. Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study , 2021, Journal for ImmunoTherapy of Cancer.
[6] C. Porta,et al. Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives. , 2021, Cancer treatment reviews.
[7] S. Salas,et al. 957O Long-term follow-up of patients (pts) with human papillomavirus (HPV)–associated malignancies treated with bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1 , 2021, Annals of Oncology.
[8] N. Normanno,et al. Cetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial. , 2021, JAMA oncology.
[9] C. Borg,et al. Present and Future Research on Anal Squamous Cell Carcinoma , 2021, Cancers.
[10] S. Steigen,et al. Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.
[11] J. Hubbard,et al. Research on Anal Squamous Cell Carcinoma: Systemic Therapy Strategies for Anal Cancer , 2021, Cancers.
[12] A. Jácome,et al. Emerging and Experimental Agents for Anal Cancer: What is New? , 2021, Journal of experimental pharmacology.
[13] M. Abba,et al. A clinical and molecular portrait of non-metastatic anal squamous cell carcinoma , 2021, Translational oncology.
[14] J. Becker,et al. Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer. , 2021, Cancer treatment reviews.
[15] J. Lack,et al. TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers , 2021, Nature Medicine.
[16] C. Borg,et al. Pooled analysis of 115 patients from updated data of Epitopes-HPV01 and Epitopes-HPV02 studies in first-line advanced anal squamous cell carcinoma , 2020, Therapeutic advances in medical oncology.
[17] S. Salas,et al. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies , 2020, Journal for ImmunoTherapy of Cancer.
[18] Y. Najjar,et al. 407 Preliminary safety, pharmacokinetics/pharmacodynamics, and antitumor activity of XmAb20717, a PD-1 x CTLA-4 bispecific antibody, in patients with advanced solid tumors , 2020 .
[19] K. Spindler,et al. LBA42 POD1UM-202: Phase II study of retifanlimab in patients (pts) with squamous carcinoma of the anal canal (SCAC) who progressed following platinum-based chemotherapy , 2020 .
[20] C. Berking,et al. Evaluation of PD-L1 Expression and HPV Genotyping in Anal Squamous Cell Carcinoma , 2020, Cancers.
[21] G. Martini,et al. How I treat anal squamous cell carcinoma , 2020, ESMO open.
[22] I. Wistuba,et al. 403MO Atezolizumab in combination with bevacizumab for patients with unresectable/metastatic anal cancer , 2020 .
[23] C. Borg,et al. Anti-Telomerase CD4+ Th1 Immunity and Monocytic-Myeloid-Derived-Suppressor Cells Are Associated with Long-Term Efficacy Achieved by Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) in Advanced Anal Squamous Cell Carcinoma: Translational Study of Epitopes-HPV01 and 02 Trials , 2020, International journal of molecular sciences.
[24] F. Ciardiello,et al. Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer , 2020, ESMO Open.
[25] J. Tabernero,et al. Clinical development of therapies targeting TGFβ: current knowledge and future perspectives. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] L. Rajdev,et al. Immunotherapy in Anal Cancer , 2020, Current Oncology Reports.
[27] A. Benson,et al. International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] H. Heslop,et al. Virus-specific T cells for malignancies - then, now and where to? , 2020, Current stem cell reports.
[29] P. Ascierto,et al. Pembrolizumab for previously treated advanced anal squamous cell carcinoma: Pooled results from the KEYNOTE-028 and KEYNOTE-158 studies. , 2020 .
[30] B. Pessia,et al. Squamous cell anal cancer: Management and therapeutic options , 2020, Annals of medicine and surgery.
[31] J. Debus,et al. RADIANCE – Radiochemotherapy with or without Durvalumab in the treatment of anal squamous cell carcinoma: A randomized multicenter phase II trial , 2020, Clinical and translational radiation oncology.
[32] F. Bidard,et al. Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial , 2020, BMC Cancer.
[33] J. Squire,et al. Emerging role of PTEN loss in evasion of the immune response to tumours , 2020, British Journal of Cancer.
[34] M. Fakih,et al. A phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent/recurrent loco-regional or metastatic anal cancer , 2020, Oncotarget.
[35] A. Nicolas,et al. Mechanistic Signatures of Human Papillomavirus Insertions in Anal Squamous Cell Carcinomas , 2019, Cancers.
[36] Sung-Bae Kim,et al. Myeloid derived suppressor cells but not regulatory T cells are associated with adaptive immunity and clinical outcomes in anal squamous cell carcinoma , 2019, Annals of Oncology.
[37] W. Gu,et al. PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition , 2019, Front. Immunol..
[38] K. Almhanna,et al. Anal cancer and immunotherapy-are we there yet? , 2019, Translational gastroenterology and hepatology.
[39] J. Gartner,et al. T-Cell Receptor Gene Therapy for Human Papillomavirus–Associated Epithelial Cancers: A First-in-Human, Phase I/II Study , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] G. Vandermeulen,et al. Cancer DNA vaccines: current preclinical and clinical developments and future perspectives , 2019, Journal of experimental & clinical cancer research : CR.
[41] Young Uk Kim,et al. Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16–Related Cancer: A Phase 2 Clinical Trial , 2019, JAMA oncology.
[42] S. Rosenberg,et al. A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus–associated Epithelial Cancers , 2018, Clinical Cancer Research.
[43] D. Schadendorf,et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. , 2018, The Lancet. Oncology.
[44] C. Borg,et al. Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study. , 2018, The Lancet. Oncology.
[45] V. Morris,et al. Role of Immunotherapy in the Treatment of Squamous Cell Carcinoma of the Anal Canal. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.
[46] C. Rödel,et al. Anal squamous cell carcinoma - State of the art management and future perspectives. , 2018, Cancer treatment reviews.
[47] A. Zhavoronkov,et al. Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy , 2018, Nature Communications.
[48] J. Hesser,et al. Using immunotherapy to boost the abscopal effect , 2018, Nature Reviews Cancer.
[49] Joe Y. Chang,et al. Combining radiation plus immunotherapy to improve systemic immune response. , 2018, Journal of thoracic disease.
[50] M. Sawyer,et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] Aroop Sircar,et al. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β , 2018, Science Translational Medicine.
[52] F. Bidard,et al. Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study) , 2017, BMC Cancer.
[53] Jing Wang,et al. Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal , 2017, Molecular Cancer Research.
[54] Toby C. Cornish,et al. Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy , 2017, JAMA oncology.
[55] P. Sharma,et al. Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. , 2017, The Lancet. Oncology.
[56] K. Emancipator,et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[57] C. Rödel,et al. Human papilloma virus load and PD-1/PD-L1, CD8+ and FOXP3 in anal cancer patients treated with chemoradiotherapy: Rationale for immunotherapy , 2017, Oncoimmunology.
[58] V. Goh,et al. Biomarkers in anal cancer: from biological understanding to stratified treatment , 2016, British Journal of Cancer.
[59] G. Getz,et al. Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma , 2016, Clinical Cancer Research.
[60] S. Demaria,et al. Current clinical trials testing the combination of immunotherapy with radiotherapy , 2016, Journal of Immunotherapy for Cancer.
[61] C. Eng,et al. Epidermal growth factor receptor inhibition in metastatic anal cancer , 2016, Anti-cancer drugs.
[62] James X. Sun,et al. Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[63] G. Coukos,et al. Combining immunotherapy and anticancer agents: the right path to achieve cancer cure? , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[64] L. Emens,et al. The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies , 2015, Cancer Immunology Research.
[65] J. Beijnen,et al. HPV-negative squamous cell carcinoma of the anal canal is unresponsive to standard treatment and frequently carries disruptive mutations in TP53 , 2015, British Journal of Cancer.
[66] E. Høgdall,et al. Human papillomavirus genotyping and p16 expression as prognostic factors for patients with American Joint Committee on Cancer stages I to III carcinoma of the anal canal. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] J. Bosset,et al. DCF (docetaxel, cisplatin and 5-fluorouracil) chemotherapy is a promising treatment for recurrent advanced squamous cell anal carcinoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[68] Laurence Zitvogel,et al. Immunogenic cell death in cancer therapy. , 2013, Annual review of immunology.
[69] M. Moore,et al. Epidermal growth factor receptor expression in anal canal carcinoma. , 2005, American journal of clinical pathology.
[70] G. Demers,et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis , 1996, Nature Medicine.